


Serial No. 09/868,395  
Attorney Docket No. PG3612USw

### Amendments to the Claims:

Please amend the claims as follows:

Claims 1-28 (Cancelled)

Claim 29 (Currently amended): A compound of formula I:



wherein R<sup>1</sup> and R<sup>2</sup> independently represent

(i) -C<sub>1-6</sub> alkyl, -C<sub>3-8</sub> cycloalkyl or -C<sub>1-3</sub> alkylC<sub>3-8</sub> cycloalkyl,

or such a group in which alkyl or cycloalkyl is substituted by one or more halogen, -CN, nitro, hydroxy or -OC<sub>1-6</sub>alkyl groups;

(ii) -(CH<sub>2</sub>)<sub>e</sub>Ar<sup>1</sup> or -(CH<sub>2</sub>)<sub>e</sub>OAr<sup>1</sup>;

or NR<sup>1</sup>R<sup>2</sup> together represent pyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or azepinyl, or such a group fused to a benzene ring, optionally

substituted by one or more -(CO)<sub>n</sub>(CH<sub>2</sub>)<sub>t</sub>Ar<sup>1</sup>, -(CO)<sub>n</sub>C<sub>1-6</sub> alkylAr<sup>1</sup>Ar<sup>2</sup>, -(CO)<sub>n</sub>C<sub>1-6</sub>alkyl,

-(CH<sub>2</sub>)<sub>t</sub>OH, -(CH<sub>2</sub>)<sub>t</sub>O(CH<sub>2</sub>)<sub>p</sub>OH, -(CH<sub>2</sub>)<sub>t</sub>OC<sub>1-6</sub> alkyl, -O(CH<sub>2</sub>)<sub>t</sub>Ar<sup>1</sup>, -(CH<sub>2</sub>)<sub>t</sub>SO<sub>2</sub>Ar<sup>1</sup>,

piperidin-1-yl, -(CH<sub>2</sub>)<sub>t</sub>CONR<sup>8</sup>R<sup>9</sup>, -NR<sup>10</sup>(CO)<sub>n</sub>(CH<sub>2</sub>)<sub>t</sub>Ar<sup>1</sup>, -NR<sup>10</sup>(CO)<sub>n</sub>C<sub>1-3</sub>alkylC<sub>3-6</sub>

cycloalkyl, -NR<sup>10</sup>(CO)<sub>n</sub>C<sub>1-6</sub> alkylC<sub>3-6</sub> cycloalkyl, -CONR<sup>10</sup>(CH<sub>2</sub>)<sub>t</sub>Ar<sup>1</sup>, halogen,

-NHCO<sub>2</sub>C<sub>1-6</sub>alkyl, -SO<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>, -SO<sub>2</sub>C<sub>1-6</sub> alkyl or -SO<sub>2</sub>Ar<sup>2</sup> groups;

R<sup>3</sup> represents -C<sub>1-6</sub>alkylNHC(=NH)NH<sub>2</sub>, -C<sub>2-6</sub>alkenylNHC(=NH)NH<sub>2</sub>,

-C<sub>2-6</sub>alkynylNHC(=NH)NH<sub>2</sub>, -C<sub>1-6</sub>alkylNR<sup>14</sup>R<sup>18</sup>, -(CH<sub>2</sub>)<sub>h</sub>CONR<sup>14</sup>R<sup>18</sup>,

-(CH<sub>2</sub>)<sub>h</sub>COC<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>d</sub>CHNR<sup>18</sup>CONR<sup>20</sup>R<sup>21</sup>, -(CH<sub>2</sub>)<sub>m</sub>NR<sup>18</sup>CONR<sup>14</sup>R<sup>18</sup>,

-(CH<sub>2</sub>)<sub>d</sub>NR<sup>18</sup>Ar<sup>3</sup>, -(CH<sub>2</sub>)<sub>d</sub>CONR<sup>18</sup>Ar<sup>3</sup>, -(CH<sub>2</sub>)<sub>h</sub>COOR<sup>18</sup>, -(CH<sub>2</sub>)<sub>e</sub>Ar<sup>3</sup>, -O(CH<sub>2</sub>)<sub>e</sub>Ar<sup>3</sup>,

-(CH<sub>2</sub>)<sub>d</sub>CO(CH<sub>2</sub>)<sub>s</sub>Ar<sup>3</sup> or -(CH<sub>2</sub>)<sub>d</sub>OAr<sup>3</sup>;

or R<sup>3</sup> represents -(CH<sub>2</sub>)<sub>e</sub>-2,4-imidazolidinedione, -(CH<sub>2</sub>)<sub>c</sub>(piperidin-4-yl),

-(CH<sub>2</sub>)<sub>c</sub>(piperidin-3-yl), -(CH<sub>2</sub>)<sub>c</sub>(piperidin-2-yl), -(CH<sub>2</sub>)<sub>c</sub>(morpholin-3-yl) or

-(CH<sub>2</sub>)<sub>c</sub>(morpholin-2-yl) optionally substituted on nitrogen by -(CO)<sub>t</sub>C<sub>1-6</sub>alkyl,

Serial No. 09/868,395  
Attorney Docket No. PG3612USw

$-(CO)_f(CH_2)_cAr^2$  or  $-C(=NH)NH_2$ ;

or  $R^3$  represents  $-(CH_2)_2$ dibenzofuran optionally substituted by  $-C_{1-6}$ alkyl or halogen;

or  $R^3$  represents  $-(CH_2)_c$ -thioxanthen-9-one;

$R^4$  represents hydrogen,  $-C_{1-6}$  alkyl,  $-C_{1-3}$  alkyl/ $C_{3-6}$  cycloalkyl,  $-(CH_2)_qAr^2$ ,  $-C_{1-4}$ alkyl-

$X-R^7$ ,  $-C_{1-4}$ alkyl  $SO_2C_{1-4}$  alkyl,  $-C_{1-6}$ alkyl/ $NR^{12}R^{13}$  or  $-C_{1-6}$  alkyl/ $NR^{12}COC_{1-6}$  alkyl;

$R^5$  represents hydrogen, or  $R^4R^5$  together with the carbon to which they are attached form a  $C_{5-7}$  cycloalkyl ring;

$R^6$  represents hydrogen or  $-C_{1-6}$ alkyl, ~~or  $R^6$  and  $R^4$  together with the N and C atoms to which they are respectively attached form a pyrrolidine ring;~~

$R^7$  represents hydrogen,  $-(CH_2)_wNR^{12}R^{13}$ ,  $-(CH_2)_qAr^2$  or  $-(CH_2)_wNR^{12}COC_{1-6}$  alkyl;

$R^8$ ,  $R^9$ ,  $R^{16}$  and  $R^{17}$  independently represent hydrogen,  $-C_{1-6}$ alkyl,  $-C_{3-6}$ cycloalkyl,  $-C_{1-3}$ alkyl/ $C_{3-6}$  cycloalkyl,  $-C_{2-6}$ alkenyl or  $NR^8R^9$  or  $NR^{16}R^{17}$  together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or piperazinyl N-substituted by  $-C_{1-6}$  alkyl,  $-CO$ phenyl or  $-SO_2$ methyl;

$R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{15}$ ,  $R^{18}$ ,  $R^{20}$  and  $R^{21}$  independently represent hydrogen or  $-C_{1-6}$ alkyl;

$R^{14}$ ,  $R^{19}$  and  $R^{22}$  independently represent hydrogen,  $-C_{1-6}$ alkyl,  $-C_{3-6}$  cycloalkyl or  $-(CH_2)_xAr^4$  or  $NR^{14}R^{18}$  or  $NR^{15}R^{22}$  together represents morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl or N- $-C_{1-6}$ alkylpiperazinyl;

$Ar^1$  represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S optionally substituted by one or more halogen,  ~~$-C_{1-6}$ alkyl~~  $-C_{1-6}$ alkyl, hydroxy,  $-OC_{1-6}$ alkyl,  $-CF_3$ ,  $CF_3$ , nitro,  $-Ar^2$  or  $-OAr^2$  groups;

$Ar^2$  represents phenyl optionally substituted by one or more halogen,  $-C_{1-6}$ alkyl, hydroxy,  $-OC_{1-6}$ alkyl,  $-CF_3$  or nitro groups;

$Ar^3$  represents phenyl, a 5 or 6 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N or S, or such a group fused to a benzene ring, optionally substituted by one or more  $-CO(CH_2)_gAr^4$ ,  $-(CH_2)_yAr^4$ ,  $-(CH_2)_yCOAr^4$ ,  $-(CO)_aC_{1-6}$  alkyl,  $-(CO)_aC_{2-6}$  alkenyl,  $-(CO)_aC_{2-6}$  alkynyl,  $-(CO)_aC_{3-8}$ cycloalkyl,  $-(CO)_aC_{1-6}$ haloalkyl, halogen,  $-COCH_2CN$ ,  $-(CH_2)_bNR^{16}R^{17}$ ,  $-(CH_2)_bNHC(=NH)NH_2$ ,  $-CYNR^{16}(CO)_aR^{17}$ ,  $-(CH_2)_bNR^{15}COR^{19}$ ,  $-(CH_2)_bCONR^{15}R^{22}$ ,  $-(CH_2)_bNR^{15}CONR^{15}R^{22}$ ,  $-(CH_2)_bCONR^{15}(CH_2)_jNR^{15}R^{22}$ ,  $-(CH_2)_bSO_2NR^{15}R^{22}$ ,  $-(CH_2)_bSO_2NR^{15}COAr^2$ ,  $-(CH_2)_bNR^{15}SO_2R^{19}$ ,  $-SO_2R^{19}$ ,  $-SOR^{19}$ ,  $-(CH_2)_zOH$ ,

Serial No. 09/868,395  
Attorney Docket No. PG3612USw

$-\text{COOR}^{15}$ ,  $-\text{CHO}$ ,  $-\text{OC}_{1-10}\text{alkyl}$ ,  $-\text{O}(\text{CH}_2)_j\text{NR}^{15}\text{R}^{22}$ ,  $-\text{O}(\text{CH}_2)_j\text{NHC}(=\text{NH})\text{NH}_2$ ,  
 $-\text{O}(\text{CH}_2)_b\text{CONR}^{16}\text{R}^{17}$ ,  $-\text{O}(\text{CH}_2)_k\text{COOR}^{15}$ ,  $-\text{O}(\text{CH}_2)_j\text{OAr}^2$ ,  $-\text{O}(\text{CH}_2)_b\text{Ar}^2$ , 3-phenyl-2-  
pyrazolin-5-one or 4,5-dihydro-3(2H)-pyridazinone groups;

$\text{Ar}^4$  represents phenyl or a 5 or 6 membered heterocyclic aromatic ring containing 1 to  
3 heteroatoms selected from O, N and S optionally substituted by one or more  
halogen,  $-\text{C}_{1-6}\text{alkyl}$ , hydroxy,  $-\text{OC}_{1-6}\text{alkyl}$ ,  $-\text{CF}_3$ , nitro or  $-\text{CONH}_2$  groups;

X and Y independently represent O or S;

a, f, k, s and n independently represent 0 or 1;

b, c, r, x, y and z independently represent an integer 0 to 2;

d, g and u independently represent 1 or 2;

e, h, q and w independently represent an integer 1 to 3;

j and p independently represent an integer 2 to 4;

m independently represents an integer 0 to 4;

t independently represents an integer 0 to 3;

~~and~~ or salts ~~and~~ or solvates thereof.

Claim 30 (Previously presented): A compound according to claim 29 wherein  $\text{R}^4$   
represents  $-\text{C}_{1-6}\text{alkyl}$ ,  $\text{R}^5$  represents hydrogen or  $\text{R}^4\text{R}^5$ , together with the carbon to  
which they are attached, forms a cyclohexyl ring, and  $\text{R}^6$  represents hydrogen or  
methyl.

Claim 31 (Previously presented): A compound according to claim 30 wherein  $\text{R}^4$   
represents  $-\text{C}_{1-6}\text{alkyl}$  and  $\text{R}^5$  and  $\text{R}^6$  represent hydrogen.

Claim 32 (Previously presented): A compound according to claim 31 wherein  $\text{R}^4$   
represents  $-\text{CH}_2\text{CHMe}_2$  and  $\text{R}^5$  and  $\text{R}^6$  represent hydrogen.

Claim 33 (Previously presented): A compound according to claim 29 wherein  $\text{NR}^1\text{R}^2$   
together represents piperidinyl, piperazinyl, thiomorpholinyl, morpholinyl or 1,2,3,4-  
tetrahydroisoquinoline optionally substituted by a  $-(\text{CO})_n(\text{CH}_2)_r\text{Ar}^1$ ,  $-(\text{CO})_n\text{C}_{1-6}\text{alkyl}$ ,  
 $-(\text{CH}_2)_t\text{CONR}^8\text{R}^9$ ,  $-\text{NR}^{10}(\text{CO})_n(\text{CH}_2)_r\text{Ar}^1$ ,  $-\text{NR}^{10}(\text{CO})_n\text{C}_{1-3}\text{alkylC}_{3-6}\text{cycloalkyl}$ ,  
 $-\text{NR}^{10}(\text{CO})_n\text{C}_{1-6}\text{alkyldiC}_{3-6}\text{cycloalkyl}$ ,  $-(\text{CH}_2)_t\text{OC}_{1-6}\text{alkyl}$ ,  $-(\text{CH}_2)_t\text{O}(\text{CH}_2)_p\text{OH}$ ,  
piperidin-1-yl,  $-(\text{CH}_2)_t\text{OH}$  or  $-\text{CONR}^{10}(\text{CH}_2)_r\text{Ar}^1$  group.

Serial No. 09/868,395  
Attorney Docket No. PG3612USw


Claim 34 (Previously presented): A compound according to claim 33 wherein  $\text{NR}^1\text{R}^2$  together represents morpholinyl or piperazinyl optionally N-substituted by  $-(\text{CO})_n\text{C}_{1-6}$  alkyl, piperazinyl N-substituted by  $-(\text{CO})_n(\text{CH}_2)_r\text{Ar}^1$ , piperidinyl substituted by  $-\text{NR}^{10}(\text{CO})_n(\text{CH}_2)_r\text{Ar}^1$  or piperidinyl substituted by  $-(\text{CH}_2)_r\text{CONR}^8\text{R}^9$ .

Claim 35 (Previously presented): A compound according to claim 29 wherein  $\text{R}^3$  represents  $-(\text{CH}_2)_c$ -2,4-imidazolidinedione-3-yl,  $-(\text{CH}_2)_c$ -thioxanthen-9-one-3-yl,  $-(\text{CH}_2)_c\text{Ar}^3$ ,  $-\text{O}(\text{CH}_2)_c\text{Ar}^3$ ,  $-(\text{CH}_2)_d\text{OAr}^3$  or  $-(\text{CH}_2)_2$ dibenzofuran.

Claim 36 (Previously presented): A compound according to claim 35 wherein  $\text{R}^3$  represents  $-\text{OCH}_2\text{Ar}^3$ ,  $-\text{CH}_2\text{OAr}^3$  or dibenzofuran.

Claim 37 (Previously presented): A compound according to claim 36 wherein  $\text{R}^3$  represents  $-\text{CH}_2\text{OAr}^3$ .

Claim 38 (Currently amended): A compound according to claim 29 wherein  $\text{R}^4$  and  $\text{R}^5$  have the stereochemical orientation shown in formula (Ia):



Claim 39 (Currently amended): A compound selected from the group consisting of formula (I) which is:

(2S)-2-[[[(2S)-2-{[2-(2-Benzoylphenoxy)acetyl]amino}-4-methyl pentanoyl]amino]-3-{4-[[{4-[(2-phenylacetyl)amino]-1-piperidinyl}carbonyl)oxy]phenyl}propanoic acid;

Serial No. 09/868,395  
Attorney Docket No. PG3612USw

(2S)-2-((2S)-4-Methyl-2-((2-((3-(1-piperidinylcarbonyl)-2-naphthyl)oxy)acetyl)amino)pentanoyl)amino)-3-{4-((4-((2-phenylacetyl)amino)-1-piperidinyl)carbonyl)oxy}phenyl}propanoic acid;  
(2S)-3-{4-((4-((2,2-Dicyclohexylacetyl)amino)-1-piperidinyl)carbonyl)oxy}phenyl}-2-((2S)-4-methyl-2-((2-[4-(1-piperidinylcarbonyl)phenoxy]acetyl)amino)pentanoyl)amino}propanoic acid;  
(2S)-2-(((2S)-4-Methyl-2-((2-[4-(1-piperidinylcarbonyl)phenoxy]acetyl)amino)pentanoyl)amino)-3-{4-((4-morpholinylcarbonyl)oxy}phenyl}propanoic acid;  
(2S)-3-[4-((4-(Aminocarbonyl)-1-piperidinyl)carbonyl)oxy}phenyl]-2-(((2S)-4-methyl-2-((2-[4-(1-piperidinylcarbonyl)phenoxy]acetyl)amino)pentanoyl)amino}propanoic acid;  
(2S)-3-{4-((4-((2-Cyclohexylacetyl)amino)-1-piperidinyl)carbonyl)oxy}phenyl}-2-(((2S)-2-((2-(2-iodophenoxy)acetyl)amino)-4-methylpentanoyl)amino}propanoic acid;  
(2S)-3-{4-((4-((2,2-Dicyclohexylacetyl)amino)-1-piperidinyl)carbonyl)oxy}phenyl}-2-(((2S)-2-((2-(2-iodophenoxy)acetyl)amino)-4-methylpentanoyl)amino}propanoic acid;  
(2S)-2-(((2S)-2-((Dibenzo[b,d]furan-4-ylcarbonyl)amino)-4-methylpentanoyl)amino)-3-{4-((4-morpholinylcarbonyl)oxy}phenyl}propanoic acid;  
(2S)-2-(((2S)-2-((Dibenzo[b,d]furan-4-ylcarbonyl)amino)-4-methylpentanoyl)amino)-3-{4-((4-((2-phenylacetyl)amino)-1-piperidinyl)carbonyl)oxy}phenyl}propanoic acid;  
(2S)-2-(((2S)-2-((2-(2-Iodophenoxy)acetyl)amino)-4-methylpentanoyl)amino)-3-{4-((4-((2-phenylacetyl)amino)-1-piperidinyl)carbonyl)oxy}phenyl}propanoic acid;  
(2S)-3-(4-((4-Acetyl-1-piperazinyl)carbonyl)oxy}phenyl)-2-(((2S)-2-((2-(2-iodophenoxy)acetyl)amino)-4-methylpentanoyl)amino}propanoic acid;  
(2S)-3-(4-((4-Benzoyl-1-piperazinyl)carbonyl)oxy}phenyl)-2-(((2S)-2-((2-(2-iodophenoxy)acetyl)amino)-4-methylpentanoyl)amino}propanoic acid;  
(2S)-3-(4-((4-Benzoyl-1-piperazinyl)carbonyl)oxy}phenyl)-2-(((2S)-2-((2-(2,4-dichlorophenoxy)acetyl)amino)-4-methylpentanoyl)amino}propanoic acid;  
(2S)-3-[4-((4-(Aminocarbonyl)-1-piperidinyl)carbonyl)oxy}phenyl]-2-(((2S)-2-((2-(2-iodophenoxy)acetyl)amino)-4-methylpentanoyl)amino}propanoic acid;

Serial No. 09/868,395  
Attorney Docket No. PG3612USw

(2S)-2-([(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl  
pentanoyl]amino)-3-[4-({4-(1-piperidinylcarbonyl)-1-piperidinyl}carbonyl)oxy)  
phenyl]propanoic acid;  
(2S)-2-([(2S)-4-Methyl-2-({2-(2-methylphenoxy)acetyl}amino) pentanoyl]amino)-3-  
[4-({4-(1-piperidinylcarbonyl)-1-piperidinyl}carbonyl)oxy) phenyl]propanoic acid;  
(2S)-2-([(2S)-2-((Dibenzo[b,d]furan-4-ylcarbonyl)amino)-4-methyl  
pentanoyl]amino)-3-[4-({4-(1-piperidinylcarbonyl)-1-piperidinyl}carbonyl)oxy)  
phenyl]propanoic acid;  
(2S)-2-([(2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-  
methylpentanoyl]amino)-3-[4-({4-(1-piperidinylcarbonyl)-1-piperidinyl}carbonyl)  
oxy)phenyl]propanoic acid;  
(2S)-2-([(2S)-2-({2-[2-(Tert-butyl)phenoxy]acetyl}amino)-4-methyl  
pentanoyl]amino)-3-[4-({4-({4-(fluorobenzyl)amino}carbonyl)-1-piperidinyl}  
carbonyl)oxy)phenyl]propanoic acid;  
(2S)-2-([(2S)-2-({2-[(2,4-Dichlorophenoxy)acetyl]amino)-4-methyl  
pentanoyl]amino)-3-[4-({4-(4-morpholinylcarbonyl)oxy}phenyl)propanoic acid;  
(2S)-2-([(2S)-2-({2-[(2-Benzoylphenoxy)acetyl]amino)-4-methyl pentanoyl]amino)-3-  
[4-({4-(4-morpholinylcarbonyl)oxy}phenyl)propanoic acid;  
(2S)-2-([(2S)-4-Methyl-2-({2-(2-propylphenoxy)acetyl]amino) pentanoyl]amino)-3-  
[4-({4-(4-morpholinylcarbonyl)oxy}phenyl)propanoic acid;  
(2S)-2-([(2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-  
methylpentanoyl]amino)-3-[4-({4-(4-morpholinylcarbonyl)oxy}phenyl)propanoic acid;  
(2S)-2-([(2S)-2-({2-[(Benzoyloxy)carbonyl]amino)-4-methylpentanoyl] amino)-3-[4-({4-  
morpholinylcarbonyl)oxy}phenyl)propanoic acid;  
(2S)-3-[4-({4-(2-Furoyl)-1-piperazinyl}carbonyl)oxy)phenyl]-2-([(2S)-2-({2-(2-  
iodophenoxy)acetyl]amino)-4-methylpentanoyl]amino]propanoic acid;  
(2S)-2-([(2S)-2-({2-(2-Cyclohexylphenoxy)acetyl]amino)-4-methyl  
pentanoyl]amino)-3-[4-({4-(2-furoyl)-1-piperazinyl}carbonyl)oxy)phenyl] propanoic  
acid;  
(2S)-2-([(2S)-2-({2-[(1-Bromo-2-naphthyl)oxy]acetyl}amino)-4-  
methylpentanoyl]amino)-3-[4-({4-(2-furoyl)-1-piperazinyl}carbonyl)oxy)phenyl]  
propanoic acid;

Serial No. 09/868,395

Attorney Docket No. PG3612USw

(2S)-3-(4-[[4-[[2-(4-Chlorophenyl)acetyl]amino]-1-piperidinyl]carbonyl]oxy]phenyl)-2-[[((2S)-2-[[2-(2-cyclohexylphenoxy)acetyl]amino]-4-methylpentanoyl)amino]propanoic acid;

(2S)-2-[[((2S)-2-[[2-(2-Benzoylphenoxy)acetyl]amino]-4-methylpentanoyl)amino]-3-(4-[[4-[[2-(4-chlorophenyl)acetyl]amino]-1-piperidinyl]carbonyl]oxy]phenyl)propanoic acid;

(2S)-3-(4-[[4-[[2-(4-Chlorophenyl)acetyl]amino]-1-piperidinyl]carbonyl]oxy]phenyl)-2-[[((2S)-2-[[2-(2-iodophenoxy)acetyl]amino]-4-methylpentanoyl)amino]propanoic acid;

(2S)-2-[[((2S)-2-[[2-(2-(Tert-butyl)phenoxy)acetyl]amino]-4-methylpentanoyl)amino]-3-(4-[[4-[[2-(4-chlorophenyl)acetyl]amino]-1-piperidinyl]carbonyl]oxy]phenyl)propanoic acid;

(2S)-3-(4-[[4-[[2-(4-Chlorophenyl)acetyl]amino]-1-piperidinyl]carbonyl]oxy]phenyl)-2-((2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino]propanoic acid;

(2S)-3-(4-[[4-[[2-(4-Chlorophenyl)acetyl]amino]-1-piperidinyl]carbonyl]oxy]phenyl)-2-((2S)-4-methyl-2-[(2-[[3-(1-piperidinylcarbonyl)-2-naphthyl]oxy]acetyl)amino]pentanoyl)amino]propanoic acid;

(2S)-2-[[((2S)-2-[[2-(2-(Tert-butyl)phenoxy)acetyl]amino]-4-methylpentanoyl)amino]-3-{4-[[4-[[2-(2-cyclohexylacetyl)amino]-1-piperidinyl]carbonyl]oxy]phenyl}propanoic acid;

(2S)-2-[[((2S)-2-[[2-(2-(Tert-butyl)phenoxy)acetyl]amino]-4-methylpentanoyl)amino]-3-{4-[[4-[[2-(2-dicyclohexylacetyl)amino]-1-piperidinyl]carbonyl]oxy]phenyl}propanoic acid;

(2S)-2-[[((2S)-4-Methyl-2-[[2-(2-methylphenoxy)acetyl]amino]pentanoyl)amino]-3-{4-[[4-[[2-(phenylacetyl)amino]-1-piperidinyl]carbonyl]oxy]phenyl}propanoic acid;

(2S)-2-[[((2S)-2-[[2-(2-Cyclohexylphenoxy)acetyl]amino]-4-methylpentanoyl)amino]-3-{4-[[4-[[2-(phenylacetyl)amino]-1-piperidinyl]carbonyl]oxy]phenyl}propanoic acid;

(2S)-3-{4-[[4-[[2-(2-Cyclohexylacetyl)amino]-1-piperidinyl]carbonyl]oxy]phenyl}-2-[[((2S)-2-[[2-(2-cyclohexylphenoxy)acetyl]amino]-4-methylpentanoyl)amino]propanoic acid;

and salts and solvates thereof.

Serial No. 09/868,395  
Attorney Docket No. PG3612USw

Claim 40 (Currently amended): A compound selected from the group consisting of formula (I) which is:

(2S)-2-(((2S)-2-([2-(2-Iodophenoxy)acetyl]amino)-4-methyl pentanoyl)amino)-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;  
(2S)-2-(((2S)-2-([2-(2-Tert-butyl)phenoxy]acetyl]amino)-4-methyl pentanoyl)amino)-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;  
(2S)-3-(4-(((4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-(((2S)-2-([2-(2-tert-butyl)phenoxy]acetyl]amino)-4-methylpentanoyl]amino)propanoic acid;  
(2S)-2-(((2S)-2-([2-(2-Cyclohexylphenoxy)acetyl]amino)-4-methyl pentanoyl)amino)-3-{4-[(4-morpholinylcarbonyl)oxy]phenyl}propanoic acid;  
(2S)-2-(((2S)-2-([2-(2-Tert-butyl)phenoxy]acetyl]amino)-4-methyl pentanoyl]amino)-3-{4-[(4-[(2-phenylacetyl)amino]-1-piperidinyl)carbonyl]oxy}phenyl}propanoic acid;  
(2S)-3-(4-(((4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-(((2S)-2-([2-(2-tert-butyl)phenoxy]acetyl]amino)-4-methylpentanoyl]amino)propanoic acid;  
(2S)-3-(4-(((4-Acetyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-(((2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl]amino)propanoic acid;  
(2S)-2-(((2S)-2-([2-(2-Tert-butyl)phenoxy]acetyl]amino)-4-methyl pentanoyl]amino)-3-[4-([4-(2-furoyl)-1-piperazinyl]carbonyl]oxy)phenyl]propanoic acid;  
(2S)-2-(((2S)-2-[(Dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methyl pentanoyl]amino)-3-[4-([4-(2-furoyl)-1-piperazinyl]carbonyl]oxy)phenyl]propanoic acid;  
(2S)-3-(4-(((4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-(((2S)-4-methyl-2-([2-methylphenoxy]acetyl]amino)pentanoyl]amino)propanoic acid;  
(2S)-3-(4-(((4-Benzoyl-1-piperazinyl)carbonyl]oxy}phenyl)-2-(((2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl]amino)propanoic acid;  
and salts and solvates thereof.

Claim 41 (Currently amended): A compound selected from the group consisting of formula (I) which is:



Serial No. 09/868,395  
 Attorney Docket No. PG3612USw

(2S)-3-[4-({[4-Acetyl-1-piperazinyl]carbonyl}oxy)phenyl]-2-(((2S)-4-methyl-2-({2-(2-methylphenoxy)acetyl}amino)pentanoyl)amino]propanoic acid;  
 (2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-(((2S)-2-[(dibenzo[b,d]furan-4-ylcarbonyl)amino]-4-methylpentanoyl)amino) propanoic acid;  
 (2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-(((2S)-2-({2-(tert-butyl)phenoxy}acetyl}amino)-4-methylpentanoyl)amino) propanoic acid;  
 (2S)-2-(((2S)-4-Methyl-2-({2-(2-methylphenoxy)acetyl}amino) pentanoyl)amino)-3-[4-({[4-morpholinylcarbonyl}oxy)phenyl]propanoic acid;  
 (2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-(((2S)-2-({2-(2-benzoylphenoxy)acetyl}amino)-4-methylpentanoyl)amino) propanoic acid;  
 (2S)-2-(((2S)-2-({2-[4-(Aminocarbonyl)phenoxy]acetyl}amino)-4-methylpentanoyl)amino)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]propanoic acid;  
 and salts and solvates thereof.

Claim 42 (Currently amended): A compound of formula (I) which is:

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-(((2S)-4-methyl-2-({2-(2-methylphenoxy)acetyl}amino)pentanoyl)amino) propanoic acid or a salt or solvate thereof.

Claim 43 (Currently amended): A compound of formula (I) according to claim 42 which is:

(2S)-3-[4-({[4-(Aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-(((2S)-4-methyl-2-({2-(2-methylphenoxy)acetyl}amino)pentanoyl)amino) propanoic acid potassium salt or a solvate thereof.

Claim 44 (Previously presented): A pharmaceutical composition comprising a compound of formula (I) as defined in claim 29 or a pharmaceutically acceptable salt or solvate thereof in admixture with one or more pharmaceutically acceptable diluents or carriers.


Serial No. 09/868,395  
Attorney Docket No. PG3612USw

Claim 45 (Previously presented): A pharmaceutical composition comprising a compound of formula (I) according to claim 29 or a physiologically acceptable salt or solvate thereof in combination ~~together~~ with a long acting  $\beta_2$  adrenergic receptor agonist.

Claims 46 and 47 (Cancelled)

Claim 48 (Currently amended): A process for preparation of a compound ~~of formula (I) as defined in~~ according to claim 29 which comprises:

(a) ~~hydrolyzing hydrolysis of~~ a carboxylic acid ester of formula (II)



wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are as defined in claim 29 and R is a group capable of forming a carboxylic acid ester; or

(b) deprotecting a compound according to claim 29 of formula ~~(I)~~ which is protected.

Claims 49-55 (Cancelled)

Claim 56 (New): A method of inhibiting eosinophil infiltration into the lungs of a patient comprising administering an effective amount of a compound of claim 29 to a patient in need thereof.

Claim 57 (New): A method of antagonizing VLA-4 comprising administering an effective amount of a compound of claim 29 to a patient in need thereof.